Upregulation of microRNA-129-5p inhibits cell invasion, migration and tumor angiogenesis by inhibiting ZIC2 via downregulation of the Hedgehog signaling pathway in cervical cancer.

abstract：BACKGROUND AND AIM:Widespread applicability of tissue-based mRNA expression screening for Barrett esophagus (BE) is likely to require (1) accurate methods for assaying archival formalin-fixed, paraffin-embedded (FFPE) histopathology specimens taken at endoscopy, and (2) validation studies of promising biomarkers in dif...

journal_title：Cancer biology & therapy

authors： Botelho NK,Schneiders FI,Lord SJ,Freeman AK,Tyagi S,Nancarrow DJ,Hayward NK,Whiteman DC,Lord RV

更新日期：2010-07-15 00:00:00

abstract：BACKGROUND:Mutations that activate the PI3K/AKT/mTOR pathway are relatively common in urothelial (bladder) cancers, but how these pathway mutations affect AKT dependency is not known. We characterized the relationship between AKT pathway mutational status and sensitivity to the effects of the selective AKT kinase inhib...

journal_title：Cancer biology & therapy

authors： Dickstein RJ,Nitti G,Dinney CP,Davies BR,Kamat AM,McConkey DJ

更新日期：2012-11-01 00:00:00

abstract：:Bruton's tyrosine kinase (BTK) is a non-receptor tyrosine kinase that has mainly been studied in haematopoietic cells. We have investigated whether BTK is a potential therapeutic target in prostate cancer. We find that BTK is expressed in prostate cells, with the alternate BTK-C isoform predominantly expressed in pros...

journal_title：Cancer biology & therapy

authors： Kokabee L,Wang X,Sevinsky CJ,Wang WL,Cheu L,Chittur SV,Karimipoor M,Tenniswood M,Conklin DS

更新日期：2015-01-01 00:00:00

abstract：:Cell adhesion molecules (CAMs) are glycoproteins expressed on the surface of cell membranes. In normal cells, CAMs participate in a variety of biological processes including cell proliferation, migration and differentiation. In tumor cells, CAMs have been reported to function as oncogenes or tumor suppressors, in sign...

journal_title：Cancer biology & therapy

authors： Yoon KJ,Danks MK

更新日期：2009-02-01 00:00:00

abstract：:Patients with Fanconi anemia (FA) display a wide variety of defects including bone marrow failure and a high risk of developing cancer. Multiple Fanconi genes exist whose proteins form a complex that along with BRCA1 is important for the translocalization of FANCD2 to nuclear foci. With BRCA2 and RAD51, this complex i...

journal_title：Cancer biology & therapy

authors： Rogers CD,van der Heijden MS,Brune K,Yeo CJ,Hruban RH,Kern SE,Goggins M

更新日期：2004-02-01 00:00:00

abstract：:With the increasing interest in development of cytostatic anticancer drugs, the randomized discontinuation trial (RDT) design has been proved to be useful in the evaluation of their clinical activity. In the June 1, 2006 issue of the Journal of Clinical Oncology, a study by Ratain et al. uses RDT in a phase-II placebo...

journal_title：Cancer biology & therapy

authors： Jain L,Venitz J,Figg WD

更新日期：2006-10-01 00:00:00

abstract：:While several hypotheses have been put forward to explain how prostate tumors become resistant to androgen deprivation therapy, the mechanism by which prostate tumors have increased androgen concentrations as compared to the serum has been poorly explored. Using a stromal/epithelial cell co-culture model, Mizokami et ...

journal_title：Cancer biology & therapy

authors： Sharma H,Sissung TM,Pressler H,Figg WD

更新日期：2010-02-01 00:00:00

abstract：:The enzyme 8-oxoguanine glycosylase 1 (OGG1) repairs 8-oxo-2-deoxyguanosine residue (8-oxodG) an oxidatively damaged promutagenic base. Genetic variations in OGG1 gene have been shown to modulate DNA repair capacity and are related risk of tumor development. However, epidemiologic findings have been inconsistent. The ...

journal_title：Cancer biology & therapy

authors： Habib SL,Danial E,Nath S,Schneider J,Jenkinson CP,Duggirala R,Abboud HE,Thameem F

更新日期：2008-01-01 00:00:00

abstract：:The alterative reading frame (ARF) protein is unique in its capacity to interact with Mdm2 thus facilitating p53-dependent cell cycle arrest and apoptosis. ARF also acts in a p53-independent manner in which it binds to Myc and interferes with transcriptional activation by Myc thereby inhibiting Myc-induced cell prolif...

journal_title：Cancer biology & therapy

authors： Sarkar D,Fisher PB

更新日期：2006-06-01 00:00:00

abstract：:Patients with serosal (pleural or peritoneal) spread of malignancy have few definitive treatment options and consequently have a very poor prognosis. We have previously shown that photodynamic therapy (PDT) can be an effective treatment for these patients, but that the therapeutic index is relatively narrow. Here, we ...

journal_title：Cancer biology & therapy

authors： Edmonds C,Hagan S,Gallagher-Colombo SM,Busch TM,Cengel KA

更新日期：2012-12-01 00:00:00

abstract：:Prostate cancer is the second leading cause of cancer deaths among men. The availability of animal models that represent the events and factors that exist in the natural history and biology of human prostate cancer is essential in dealing with prostate cancer. In recent decades and presently, emphasis has been directe...

journal_title：Cancer biology & therapy

authors： Costello LC,Franklin RB,Zou J,Feng P,Bok R,Swanson MG,Kurhanewicz J

更新日期：2011-12-15 00:00:00

abstract：:Prior to 2011, only 2 systemic treatments were approved for the treatment of melanoma and these had limited efficacy. In the past 4 years, 6 novel agents have received FDA approval. Herein, we will focus on 4 recently published NEJM papers reporting the results of clinical trials, comprising 4 agents targeting the MAP...

journal_title：Cancer biology & therapy

authors： Massey PR,Prasad V,Figg WD,Fojo T

更新日期：2015-01-01 00:00:00

abstract：:Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib and erlotinib, are the first targeted therapy drugs approved for the treatment of advanced non-small-cell lung cancer (NSCLC). Interestingly, treatment with these small molecule, reversible EGFR-TKIs leads to more positive respo...

journal_title：Cancer biology & therapy

authors： Xu Y,Liu H,Chen J,Zhou Q

更新日期：2010-04-15 00:00:00

abstract：:The synergistic effect of combined drug therapy provides an enhanced treatment for advanced liver cancer. We aimed to investigate the underlying mechanism of cetuximab sensitization by rapamycin in hepatoma cells. Four hepatoma cell lines, HepG2, HuH7, SNU-387, and SNU-449, were treated with cetuximab or cetuximab plu...

journal_title：Cancer biology & therapy

authors： Chen W,Hu QD,Xia XF,Liang C,Liu H,Zhang Q,Ma T,Liang F,Liang TB

更新日期：2014-08-01 00:00:00

abstract：:Hypoxia is an important phenomenon in the tumor microenvironment. Hypoxic tumors are more aggressive and resistant to anti-neoplastic treatments. HIF-1alpha plays a major role in the response of tumors to hypoxia, and it is mainly responsible for the "angiogenic switch". HIF-1alpha contributes to tumor aggressiveness,...

journal_title：Cancer biology & therapy

authors： Diaz-Gonzalez JA,Russell J,Rouzaut A,Gil-Bazo I,Montuenga L

更新日期：2005-10-01 00:00:00

abstract：:The chemotherapeutic agents doxorubicin (dox) or 5-fluorouracil (5FU) are used to treat cancer cells as they cause irreparable DNA damage, inducing these aberrant cells to undergo cell death. The mediator of this process is presumed to be in part the tumor suppressor p53 which regulates genes involved in DNA repair an...

journal_title：Cancer biology & therapy

authors： Balmer MT,Katz RD,Liao S,Goodwine JS,Gal S

更新日期：2014-08-01 00:00:00

abstract：:Medulloblastoma is an aggressive primitive neuroectodermal tumor of the cerebellum that is rare in adults. Medulloblastomas fall into 4 prognostically significant molecular subgroups that are best defined by experimental gene expression profiles: the WNT pathway, sonic hedgehog (SHH) pathway, and subgroups 3 and 4 (no...

journal_title：Cancer biology & therapy

authors： Lou E,Schomaker M,Wilson JD,Ahrens M,Dolan M,Nelson AC

更新日期：2016-10-02 00:00:00

abstract：:Although HER2-targeted therapy has been shown to prolong the survival of patients with HER2-positive breast cancer, most patients eventually progress due to drug resistance. Novel treatment options are urgently needed to overcome resistance to HER2-targeted therapy. The VEGF/VEGFR (Vascular endothelial growth factor a...

journal_title：Cancer biology & therapy

authors： Danni L,Lingyun Z,Jian W,Hongfei Y,Lu X,Peng Y,Xiujuan Q,Yunpeng L,Yuee T

更新日期：2020-07-02 00:00:00

abstract：:Genes playing a role in carcinogenesis have often been identified through analysis of recurrent chromosomal rearrangements. Although such rearrangements are well known in leukemias, lymphomas, and sarcomas, they have not been well characterized in carcinomas. In the October 28, 2005 issue of Science, a study by Tomlin...

journal_title：Cancer biology & therapy

authors： Ahlers CM,Figg WD

更新日期：2006-03-01 00:00:00

abstract：:KRAS mutational status has been shown to be a predictive biomarker of resistance to anti-EGFR monoclonal antibody (mAb) therapy in patients with metastatic colorectal cancer. We report the spectrum of KRAS mutation in 1506 patients with colorectal cancer and the identification and characterization of rare insertion mu...

journal_title：Cancer biology & therapy

authors： Tong JH,Lung RW,Sin FM,Law PP,Kang W,Chan AW,Ma BB,Mak TW,Ng SS,To KF

更新日期：2014-06-01 00:00:00

abstract：:As a kinase at the crossroads of numerous metabolic and cell growth signaling pathways, glycogen synthase kinase-3 beta (GSK-3β) is a highly desirable therapeutic target in cancer. Despite its involvement in pathways associated with the pathogenesis of several malignancies, no selective GSK-3β inhibitor has been appro...

journal_title：Cancer biology & therapy

authors： Sahin I,Eturi A,De Souza A,Pamarthy S,Tavora F,Giles FJ,Carneiro BA

更新日期：2019-01-01 00:00:00

abstract：:Onconase (Onc), a ribonuclease from oocytes or early embryos of Northern Leopard frog (Rana pipiens), is cytostatic and cytotoxic to a variety of tumor lines in vitro, inhibits growth of tumors in animal in vivo models and is currently in Phase IIIb clinical trials for malignant mesothelioma where it displays antitumo...

journal_title：Cancer biology & therapy

authors： Ita M,Halicka HD,Tanaka T,Kurose A,Ardelt B,Shogen K,Darzynkiewicz Z

更新日期：2008-07-01 00:00:00

abstract：:The reported incidence of pancreatic neuroendocrine tumors (PanNETs) has increased, due in large part to improvements in detection and awareness. However, therapeutic options are limited and a critical need exists for understanding a more thorough characterization of the molecular pathology underlying this disease. Th...

journal_title：Cancer biology & therapy

authors： Lin W,Francis JM,Li H,Gao X,Pedamallu CS,Ernst P,Meyerson M

更新日期：2016-12-01 00:00:00

abstract：:Recent reports have shown that cancer stem cells exist in many malignancies. Side population (SP) cells are used to enrich cancer stem-like cells in many cell lines and fresh tumor specimens. In this study, we cultured primary esophageal squamous cell carcinoma (ESCC) cells from ESCC tissue specimens. SP cells from pr...

journal_title：Cancer biology & therapy

authors： Li H,Gao Q,Guo L,Lu SH

更新日期：2011-06-01 00:00:00

abstract：:Antitumor imidazoacridinone C-1311 is a DNA-reactive topoisomerase II and FLT3 receptor tyrosine kinase inhibitor. Here, we demonstrate the mechanism of C-1311 inhibitory action on novel targets: hypoxia-inducible factor-1α (HIF-1α), vascular-endothelial growth factor (VEGF), and angiogenesis. In a cell-free system, C...

journal_title：Cancer biology & therapy

authors： Paradziej-Łukowicz J,Skwarska A,Peszyńska-Sularz G,Brillowska-Dąbrowska A,Konopa J

更新日期：2011-10-01 00:00:00

abstract：:We investigated the expression of annexin-1 (ANXA1) in thyroid carcinoma cell lines and in thyroid cancers with a different degree of differentiation. The highest level of ANXA1 expression examined by Western blotting was detected in the papillary carcinoma cells (NPA) and in the follicular cells (WRO). On the other h...

journal_title：Cancer biology & therapy

authors： Petrella A,Festa M,Ercolino SF,Zerilli M,Stassi G,Solito E,Parente L

更新日期：2006-06-01 00:00:00

abstract：:Every year, 12,000 people in the U.S. die from renal cell carcinoma. Current therapies include partial or complete nephrectomy or treatments such as administration of IFN-alpha and/or interleukins that are moderately effective, at best. Moreover, the current therapies are invasive and inefficient and new therapies are...

journal_title：Cancer biology & therapy

authors： VanOosten RL,Moore JM,Karacay B,Griffith TS

更新日期：2005-10-01 00:00:00

abstract：:Krüppel-Like Factor 4 (KLF4) functions as a tumor suppressor in some cancers, but its molecular mechanism is not clear. Our recent study also showed that the expression of KLF4 is dramatically reduced in primary lung cancer tissues. To investigate the possible role of KLF4 in lung cancer, we stably transfected KLF4 in...

journal_title：Cancer biology & therapy

authors： Zhou Y,Hofstetter WL,He Y,Hu W,Pataer A,Wang L,Wang J,Zhou Y,Yu L,Fang B,Swisher SG

更新日期：2010-04-01 00:00:00

abstract：:The mitochondrial production of reactive oxygen species has been implicated in the anticancer activity of furanonaphthoquinone. However, the mechanism of the activation remains elusive. In the current study, we found that treatment of HeLa cells with 2-methyl-5(or -8)-hydroxy-furanonaphthoquinone (FNQ13) induces mitoc...

journal_title：Cancer biology & therapy

authors： Simamura E,Hirai K,Shimada H,Koyama J,Niwa Y,Shimizu S

更新日期：2006-11-01 00:00:00

abstract：PURPOSE:Fibroblast Activation Protein (FAP) is a tumor fibroblast protease that has been shown to potentiate colorectal cancer growth. The clinical impact of FAP inhibition was tested using Val-boroPro (Talabostat), the first clinical inhibitor of FAP enzymatic activity, in a phase II study of patients with metastatic ...

journal_title：Cancer biology & therapy

authors： Narra K,Mullins SR,Lee HO,Strzemkowski-Brun B,Magalong K,Christiansen VJ,McKee PA,Egleston B,Cohen SJ,Weiner LM,Meropol NJ,Cheng JD

更新日期：2007-11-01 00:00:00